These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 31068147)

  • 21. De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-Infected Tissues: Implications for Primary Letermovir Resistance.
    Jo H; Kwon DE; Han SH; Min SY; Hong YM; Lim BJ; Lee KH; Jo JH
    J Infect Dis; 2020 Apr; 221(9):1480-1487. PubMed ID: 31802131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation.
    Frietsch JJ; Michel D; Stamminger T; Hunstig F; Birndt S; Schnetzke U; Scholl S; Hochhaus A; Hilgendorf I
    Mediterr J Hematol Infect Dis; 2019; 11(1):e2019001. PubMed ID: 30671207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.
    Phoompoung P; Ferreira VH; Tikkanen J; Husain S; Viswabandya A; Kumar D; Humar A
    Transplantation; 2020 Feb; 104(2):404-409. PubMed ID: 32000236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
    Pearston AP; Ingemi AI; Ripley K; Wilson TJ; Gruber J; McMahon M; Sutton S; Khardori N
    Transplant Proc; 2021 May; 53(4):1284-1287. PubMed ID: 33715819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.
    Chou S
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
    Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
    Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.
    Hantz S; Garnier-Geoffroy F; Mazeron MC; Garrigue I; Merville P; Mengelle C; Rostaing L; Saint Marcoux F; Essig M; Rerolle JP; Cotin S; Germi R; Pillet S; Lebranchu Y; Turlure P; Alain S;
    J Antimicrob Chemother; 2010 Dec; 65(12):2628-40. PubMed ID: 20961907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).
    Lischka P; Michel D; Zimmermann H
    J Infect Dis; 2016 Jan; 213(1):23-30. PubMed ID: 26113373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study.
    Veit T; Munker D; Barton J; Milger K; Kauke T; Meiser B; Michel S; Zoller M; Nitschko H; Keppler OT; Behr J; Kneidinger N
    Am J Transplant; 2021 Oct; 21(10):3449-3455. PubMed ID: 34118118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir.
    Giménez E; Guerreiro M; Torres I; Aguilar C; Albert E; Hernández-Boluda JC; Hernani R; Pérez A; Amat P; Piñana JL; Montoro J; Solano C; Navarro D
    Transpl Infect Dis; 2023 Apr; 25(2):e14021. PubMed ID: 36748748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
    Saltiel G; Faure E; Assaf A; Chopin MC; Moreau F; Faure K; Goeminne C; Vuotto F
    Clin Transplant; 2024 May; 38(5):e15327. PubMed ID: 38686437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-resistant cytomegalovirus: clinical implications of specific mutations.
    Razonable RR
    Curr Opin Organ Transplant; 2018 Aug; 23(4):388-394. PubMed ID: 29794552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products.
    Komatsu TE; Hodowanec AC; Colberg-Poley AM; Pikis A; Singer ME; O'Rear JJ; Donaldson EF
    Antiviral Res; 2019 Sep; 169():104549. PubMed ID: 31279814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Letermovir for Primary and Secondary Cytomegalovirus Prophylaxis in Abdominal Organ Transplantation: A Single Center Experience.
    Ibrahim D; Byrns J; Maziarz E; Alexander BD; Saullo JL
    J Pharm Pract; 2024 Jun; 37(3):770-779. PubMed ID: 37280011
    [No Abstract]   [Full Text] [Related]  

  • 36. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
    Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
    Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data.
    Mori Y; Jinnouchi F; Takenaka K; Aoki T; Kuriyama T; Kadowaki M; Odawara J; Ueno T; Kohno K; Harada T; Yoshimoto G; Takase K; Henzan H; Kato K; Ito Y; Kamimura T; Ohno Y; Ogawa R; Eto T; Nagafuji K; Akashi K; Miyamoto T
    Bone Marrow Transplant; 2021 Apr; 56(4):853-862. PubMed ID: 33139867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation.
    Tan CA; Palen L; Su Y; Li Y; Gennarelli RL; Perales MA; Cohen N; Papanicolaou GA; Shah GL; Seo SK
    Transplant Cell Ther; 2024 Aug; 30(8):792.e1-792.e12. PubMed ID: 38838781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Management of cytomegalovirus infection after hematopoietic stem cell transplantation].
    Mori T
    Rinsho Ketsueki; 2019; 60(9):1337-1340. PubMed ID: 31597861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Developments in the Management of Cytomegalovirus Infection After Transplantation.
    Meesing A; Razonable RR
    Drugs; 2018 Jul; 78(11):1085-1103. PubMed ID: 29961185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.